skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

もっと見る

Resources

もっと見る

もっと見る

Products

もっと見る

もっと見る

84 Total results for product and free and sample content found

Pharmaprojects: 医薬品開発パイプラインのデータベース

To infinity and beyond: how far can mRNA vaccine technology go?

 To infinity and beyond: how far can mRNA vaccine technology go?

With over 63 million confirmed cases and over 1.4 million deaths worldwide as of the start of December, the COVID-19 pandemic has certainly lit a fire under the pharmaceutical industry in the pursuit of therapeutics. In the process, with the recent emergency use authorisation in the UK for Pfizer and BioNTech’s BNT-162b2 vaccine, and the 94.5% efficacy reported by Moderna for its mRNA-1273 vaccine, a new technology has shot to the forefront: the mRNA vaccine.

Topic Diseases Drug Development Landscape Vaccines

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

mHealth and Research in Oncology

mHealth and Research in Oncology

The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit. 

Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biom...

Gene therapy manufacturers

Gene therapy manufacturers

Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.

Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor...

Deconstructing the KRAS+ market opportunity

Deconstructing the KRAS+ market opportunity

With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target

Topic biopharmaceutical drug-review

Strategic Transactions

2019 IPOs Startup Firms Grab Nearly One-Third Of Total Proceeds

Last year, a total of 67 biopharma and medtech companies completed initial public offerings (IPOs), raising for $8.55bn combined.

Topic drug-pricing

In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース, Citeline

Pipeline-In-A-Pill: Still A Winning Strategy?

Pipeline-In-A-Pill: Still A Winning Strategy?

“Pipeline-in-a-pill” has increasingly entered the biopharma executive’s vernacular, denoting an attractive asset that has considerable sales potential owing to the number of discrete patient populations it can target. While the phrase or concept may be in vogue, in reality it is one of the many guises or iterations of lifecycle management.

Topic biopharmaceutical drug-pricing drug-review drug-development-landscape

In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

Pharma R&D’s COVID-19 Scar

Pharma R&D’s COVID-19 Scar

Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.

Topic Coronavirus research

How pharma and biotech are using AI and advanced analytics to deliver successful outcomes

How pharma and biotech are using AI and advanced analytics to deliver successful outcomes

AI applications are as varied as the industry sectors that use them, and pharma has discovered the specific types of AI most useful in achieving faster, more positive results across a wide range of industry activities. 

Big Data's Big Challenge

Big Data's Big Challenge

Pharmaceutical industry experts agree that the future of pharma depends on the use of Big Data to predict upcoming events and markets, gain insights into new opportunities, and understand the implications of competitors’ activities.  

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問合せの際は下記メールアドレスまたは各営業スタッフまでご連絡下さいますようご協力をお願い申し上げます。

インフォーマインテリジェンス合同会社
ファーマインテリジェンス
inquiry.jp@informa.com

*Omdia(ICT産業の情報)に関するお問い合わせはこちら
Contact_OmdiaJapan@omdia.com


オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。